
tigenix
Takeda, TiGenix Announce Phase III Trial Results For Crohn’s Disease Drug
A significantly greater proportion of patients in the treatment group versus the placebo group achieved combined remission at week 24.

A significantly greater proportion of patients in the treatment group versus the placebo group achieved combined remission at week 24.